Nutriband Inc. (NASDAQ: NTRB) announced that CEO Gareth Sheridan is featured in a new documentary by independent journalist and filmmaker Nick Shirley examining the opioid crisis in the United States. The documentary, which focuses on the devastating impact of opioid abuse, provides a platform for Sheridan to discuss pharmaceutical innovation and technologies that could help address the crisis. Sheridan highlights Nutriband's AVERSA™ abuse-deterrent platform, which is designed to reduce the risk of abuse, misuse, diversion, and accidental exposure associated with high-risk medications while preserving access for patients with legitimate medical needs.
The inclusion of Sheridan in the documentary underscores the importance of industry-led solutions to the opioid epidemic, which continues to claim tens of thousands of lives annually in the U.S. By showcasing AVERSA™, Nutriband positions itself at the forefront of efforts to develop safer pharmaceutical products. The technology can be incorporated into any transdermal patch to deter abuse, making it a versatile tool in the fight against opioid misuse. This exposure could enhance Nutriband's visibility among investors, healthcare professionals, and the public, potentially accelerating adoption of its products.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA™ technology. This patch aims to provide pain relief while minimizing the potential for abuse, a critical need given the high abuse potential of fentanyl. The company's focus on transdermal delivery systems aligns with broader industry trends toward non-invasive, patient-friendly drug administration. For more information, visit www.nutriband.com.
The documentary featuring Sheridan is part of a growing national conversation about opioid addiction and the role of pharmaceutical innovation in mitigating it. By participating, Nutriband not only showcases its technology but also contributes to public education on the crisis. This aligns with the company's mission to develop products that address unmet medical needs while reducing the risk of abuse. The full press release can be viewed at https://ibn.fm/usSNL.
InvestorWire (InvestorWire), a specialized communications platform, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB.
